Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA7 | P43166 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP8 | P22894 | 2/20 | 0.30 |
| ▸ | MMP14 | P50281 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21556098 | 0.73 | ALDH1A1 (0.39) | ALDH1A1HSD17B10TDP1TSHRKMT2A | |
| SCHEMBL67837 | 0.64 | PKM (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6108870 | 0.64 | PKM (0.67) | CA12CA1CA2CA7CA9 | |
| Methylene Chloride SCHEMBL28109382 | 0.63 | PKM (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1169534 | 0.63 | CA12 (0.66) | CA12CA1CA2CA7CA9 | |
| SCHEMBL433497 | 0.63 | HTT (0.58) | ALDH1A1HSD17B10TDP1TSHRKMT2A | |
| SCHEMBL9720036 | 0.63 | HTT (0.58) | ALDH1A1HSD17B10TDP1TSHRKMT2A | |
| SCHEMBL14605568 | 0.63 | ALDH1A1 (0.30) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL651902 | 0.62 | ALDH1A1 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13570962 | 0.62 | CA12 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472386-B2 | Bile acid derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472386-B2 | Bile acid derivatives as FXR agonists and methods of use thereof | NR1H4, GPBAR1, SLC10A1 | CA12 2895/4885CA1 2692/4885CA2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.